Furthermore, with the growing trend among companies to outsource clinical work to contract research organizations, contract manufacture their products, and enter partnerships with other companies to increase their competitiveness, the opportunities for emerging countries for R&D and manufacturing are expected to open up considerably. Frost & Sullivan believes that generics, biotechnology, and specialist-driven therapies will drive the pharmaceutical market in countries such as Malaysia.